» Articles » PMID: 21366474

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-specific Death

Abstract

Background: The extent to which diabetes mellitus or hyperglycemia is related to risk of death from cancer or other nonvascular conditions is uncertain.

Methods: We calculated hazard ratios for cause-specific death, according to baseline diabetes status or fasting glucose level, from individual-participant data on 123,205 deaths among 820,900 people in 97 prospective studies.

Results: After adjustment for age, sex, smoking status, and body-mass index, hazard ratios among persons with diabetes as compared with persons without diabetes were as follows: 1.80 (95% confidence interval [CI], 1.71 to 1.90) for death from any cause, 1.25 (95% CI, 1.19 to 1.31) for death from cancer, 2.32 (95% CI, 2.11 to 2.56) for death from vascular causes, and 1.73 (95% CI, 1.62 to 1.85) for death from other causes. Diabetes (vs. no diabetes) was moderately associated with death from cancers of the liver, pancreas, ovary, colorectum, lung, bladder, and breast. Aside from cancer and vascular disease, diabetes (vs. no diabetes) was also associated with death from renal disease, liver disease, pneumonia and other infectious diseases, mental disorders, nonhepatic digestive diseases, external causes, intentional self-harm, nervous-system disorders, and chronic obstructive pulmonary disease. Hazard ratios were appreciably reduced after further adjustment for glycemia measures, but not after adjustment for systolic blood pressure, lipid levels, inflammation or renal markers. Fasting glucose levels exceeding 100 mg per deciliter (5.6 mmol per liter), but not levels of 70 to 100 mg per deciliter (3.9 to 5.6 mmol per liter), were associated with death. A 50-year-old with diabetes died, on average, 6 years earlier than a counterpart without diabetes, with about 40% of the difference in survival attributable to excess nonvascular deaths.

Conclusions: In addition to vascular disease, diabetes is associated with substantial premature death from several cancers, infectious diseases, external causes, intentional self-harm, and degenerative disorders, independent of several major risk factors. (Funded by the British Heart Foundation and others.).

Citing Articles

Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product-receptor axis.

Matsui T, Sotokawauchi A, Nishino Y, Koga Y, Yamagishi S Mol Med. 2025; 31(1):88.

PMID: 40050708 PMC: 11887197. DOI: 10.1186/s10020-025-01138-0.


Old drugs, new challenges: reassigning drugs for cancer therapies.

Czechowicz P, Wiech-Walow A, Slawski J, Collawn J, Bartoszewski R Cell Mol Biol Lett. 2025; 30(1):27.

PMID: 40038587 PMC: 11881393. DOI: 10.1186/s11658-025-00710-0.


The Asia-Pacific Body Mass Index Classification and New-Onset Chronic Kidney Disease in Non-Diabetic Japanese Adults: A Community-Based Longitudinal Study from 1998 to 2023.

Okawa Y, Mitsuhashi T, Tsuda T Biomedicines. 2025; 13(2).

PMID: 40002785 PMC: 11853003. DOI: 10.3390/biomedicines13020373.


Association between serum vitamin D level and cardiovascular disease in Chinese patients with type 2 diabetes mellitus: a cross-sectional study.

Zhang N, Wang Y, Li W, Wang Y, Zhang H, Xu D Sci Rep. 2025; 15(1):6454.

PMID: 39987347 PMC: 11846893. DOI: 10.1038/s41598-025-90785-8.


The relationship between hepatic enzymes, prediabetes, and diabetes in the Azar cohort population.

Faramarzi E, Mehrtabar S, Molani-Gol R, Dastgiri S BMC Endocr Disord. 2025; 25(1):41.

PMID: 39953488 PMC: 11827479. DOI: 10.1186/s12902-025-01871-x.


References
1.
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

2.
El-Serag H, Hampel H, Javadi F . The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4(3):369-80. DOI: 10.1016/j.cgh.2005.12.007. View

3.
Parr C, Batty G, Lam T, Barzi F, Fang X, Ho S . Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol. 2010; 11(8):741-52. PMC: 4170782. DOI: 10.1016/S1470-2045(10)70141-8. View

4.
Danesh J, Lewington S, Thompson S, Lowe G, Collins R, Kostis J . Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005; 294(14):1799-809. DOI: 10.1001/jama.294.14.1799. View

5.
Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R . Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009; 6(12):e1000201. PMC: 2791167. DOI: 10.1371/journal.pmed.1000201. View